Justice Department Briefing 2026-01-21
Estimated reading time: 5 minutes
1. Importer of Controlled Substances Application: Mylan Pharmaceuticals Inc.
Sub: Justice Department, Drug Enforcement Administration
Content: Mylan Pharmaceuticals Inc. has applied to be registered as an importer of basic class(es) of controlled substance(s). Refer to Supplementary Information listed below for further drug information.
2. Inflation Adjustment for EOIR OBBBA Fees; Fiscal Year 2026
Sub: Justice Department, Executive Office for Immigration Review
Content: The Department of Justice (“Department”) is announcing inflationary adjustments to immigration-related fees for filings with the Executive Office for Immigration Review (“EOIR”) under the One Big Beautiful Bill Act (“OBBBA”) for Fiscal Year (“FY”) 2026. OBBBA requires the Attorney General to annually adjust for inflation the OBBBA fees that EOIR collects. This notice sets out the EOIR-collected OBBBA fees for the remainder of FY 2026 and their effective dates.
3. United States of America et al. v. RealPage, Inc. et al. Proposed Final Judgment and Competitive Impact Statement
Sub: Justice Department, Antitrust Division
Legal Disclaimer
This article includes content collected from the Federal Register (federalregister.gov). The content is not an official government publication. This article is for informational purposes only and does not constitute legal advice. For case-specific consultation, please
contact us.
Read our full
Legal Disclaimer, which also includes information on translation accuracy.
